TRPML1 screening using automated electrophysiology provides a robust and efficient platform for ion channel drug discovery. Sygnature Discovery leverages this approach to support compound profiling, mechanism of action studies and lead optimization.
Introduction
Glucose-dependent insulinotropic polypeptide (GIP) receptor, a member of the G protein-coupled receptor (GPCR) family, serves as the primary mediator of GIP’s physiological effects. Through its activation, GIP receptor signalling influences various cellular pathways, including those involved in insulin release, adipogenesis, and gastrointestinal function. Found primarily in pancreatic β-cells and adipocytes, GIP receptors mediate insulin release and impact lipid metabolism, implicating them in the development of obesity and related metabolic disorders. Targeting GIP receptors presents a promising therapeutic strategy for managing obesity and type 2 diabetes, with pharmaceutical interventions offering potential avenues for improving metabolic health and addressing obesity-related complications. Understanding the intricate mechanisms underlying GIP receptor signalling provides valuable insights into the pathophysiology of metabolic diseases and facilitates the development of novel therapeutic interventions.
